Company Filing History:

7 out of 12

Istituto Gentili S.p.a.

patents

2 out of 15

Abiogen Pharma S.p.a.

Years Active: 1986-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9943540 - Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid (2018-04-17),

2. 6387674 - Catalytic monoclonal antibodies with protease activity for selective lysis of protein component of plaques aggregates pathological conditions (2002-05-14),

3. 5856358 - Mono- and disulfo-substituted anthraquinones and their use for the (1999-01-05),

4. 5466682 - Acylamino-alkyliden-hydroxy-bisphosphonic acids esters and salts (1995-11-14),

5. 5451606 - Anthraquinone compounds useful to treat osteoarticular conditions, (1995-09-19),

6. 5362750 - 4,5-dihydroxy- and 4,5,8-trihydroxy- (1994-11-08),

7. 5330981 - Arylalkyl esters of (1994-07-19),

8. 4814326 - Pharmaceutical compositions based on diphosphonates for the treatment of (1989-03-21),

9. 4621077 - Pharmacologically active biphosphonates, process for the preparation (1986-11-04),

10. 4578376 - Pharmaceutical compositions for the treatment of osteopathias (1986-03-25),

Title: **Exploring the Innovations of Inventor Sergio Rosini**

Introduction

Sergio Rosini, an accomplished inventor based in Ospedaletto, Italy, has made significant contributions to the field of pharmaceutical science. With two patents under his belt, Rosini is recognized for his innovative approaches to treating complex health conditions. His work, primarily focused on formulations and monoclonal antibodies, reflects a commitment to advancing medical science.

Latest Patents

Sergio Rosini holds two notable patents that highlight his innovative capabilities:

1. **Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid**: This patent discloses pharmaceutical compositions that incorporate clodronic acid and hyaluronic acid or their salts as active constituents, combined with suitable vehicles to optimize effectiveness.

2. **Catalytic monoclonal antibodies with protease activity for selective lysis of protein component of plaques in pathological conditions**: This invention involves catalytic monoclonal antibodies (abzymes) with selective protease activity targeting pathologies characterized by the presence of protein-based plaques and fibrillar aggregates. The patent details methods for preparation and application as medicaments for conditions such as Alzheimer’s disease, amyloidosis, atherosclerosis, and prion diseases.

Career Highlights

Sergio Rosini's professional journey is marked by his tenure at Abiogen Pharma S.p.A., a company renowned for its focus on innovative pharmaceutical solutions. His role at Abiogen allows him to advance his research while contributing to products that improve patient outcomes.

Collaborations

Throughout his career, Sergio has collaborated with talented professionals, including his coworker Silvia Trasciatti. This partnership has proven beneficial in driving innovation forward and enhancing the quality of their pharmaceutical developments.

Conclusion

Sergio Rosini exemplifies the spirit of innovation in the pharmaceutical industry. His patents not only underscore his expertise but also represent significant advances in the treatment of chronic and complex conditions. As he continues to develop new solutions, Rosini remains a pivotal figure in the realm of medical innovation, inspiring future advancements in health care.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com